Category Archives: Corporate

Latest From Corporate

UK Bioscience Forum: Confronting Common Challenges

Jim_London115x76

This week, BIO’s President and CEO Jim Greenwood delivered a plenary address to attendees at the UK Bioscience Forum in London, England. Below are excerpts from his speech: We can work together to build the right framework to support innovation. From the way we fund research, to how we protect innovations, to how we attract investment and streamline regulatory approval. The UK has the right innovation ecosystem in place to grow as a global biotech Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

Ask CA Governor Brown To Sign SB 598

Jim Greenwood

California’s Assembly and Senate have both overwhelmingly passed Senate Bill 598, legislation that creates a pathway for the substitution of interchangeable biologic medicines. Despite fierce opposition from insurance companies and large pharmacy chains, it is now on its way to the Governor’s desk. It’s critical for him to understand that this issue is one of the highest priorities for patients, healthcare providers and the life sciences industry. Senate Bill 598 is needed now to update Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Welcomes Five New Board Members

Jim Greenwood

BIO elected five new members to its Board of Directors, voted upon at this year’s Board Meetings, held last week in Washington, DC. The following individuals were elected to the Health Section Governing Board: Francois Nader, President & CEO of NPS Pharmaceuticals, Inc. Anna Protopapas, President of Millennium: The Takeda Oncology Company Allen Waxman, Senior Vice President and General Counsel of Eisai, Inc. Klaus Wilgenbus, Senior Vice President, Business Development & Licensing of Boehringer Ingelheim Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags:

State Legislation Needed For Substitution of Interchangeable Biologics

Copyright sanofi pasteur

A great deal of the media coverage relating to California’s Senate Bill 598  neglects to mention a key issue in the biosimilars debate. This bill – or legislation similar to it – is essential to allow for the eventual substitution of interchangeable biologic therapies in the state of California. State laws governing prescription drug substitution were written before the advent of biosimilars and do not take the complexity of biologics into account. California, along with Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Jobs: The Talent Hub for Biotechnology

Jim Greenwood

The Biotechnology Industry Organization is proud to launch BIO Jobs, an online career resource where you can find the industry’s leading biotechnology employment opportunities all in one place. Visit jobs.bio.org to: Search for and quickly apply to a variety of positions available worldwide Set up job alerts so you are immediately notified any time a job is posted that matches your skills or interests Create an anonymous job seeker profile or upload your resume anonymously Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,